Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From NantWorks, LLC
Private Company Edition: Nine new venture capital mega-rounds include Insilico’s series C, $250m from Blackstone for a CAR-T therapy spinout from Intellia and a $210m series B round for Umoja.
The latest oncology development news and highlights from our US FDA Performance Tracker.
While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.
Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter.
- In Vitro Diagnostics
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
- Altor BioScience Corporation
- Altor BioScience, LLC
- IgDraSol, Inc.
- ImmunityBio, Inc.
- NantCell, Inc.